With 53976.0 shares changed hands, the volume of the stock remained lighter than its average volume of 92850.0 shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $6.7909 whereas the lowest price it dropped to was $6.2816. The 52-week range on ACTU shows that it touched its highest point at $11.99 and its lowest point at $5.50 during that stretch. It currently has a 1-year price target of $29.00.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ACTU was up-trending over the past week, with a rise of 13.23%, but this was down by -32.41% over a month. Three-month performance dropped to -4.63% while six-month performance fell -17.42%. A look at the trailing 12-month EPS for ACTU yields -1.30 with Next year EPS estimates of -1.33. For the next quarter, that number is -0.27. This implies an EPS growth rate of 66.26% for this year and -21.21% for next year.
Float and Shares Shorts:
At present, 19.53 million ACTU shares are outstanding with a float of 5.83 million shares on hand for trading. On 2025-06-13, short shares totaled 0.24 million, which was 123.00000499999999 higher than short shares on 1747267200. In addition to Mr. Daniel M. Schmitt as the firm’s CEO, President & Director, Dr. Andrew P. Mazar Ph.D. serves as its Co-Founder & COO.
Institutional Ownership:
Through their ownership of 0.53531 of ACTU’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, ACTU reported revenue of $0.0 and operating income of -$6365584.0. The EBITDA in the recently reported quarter was -$6311961.0 and diluted EPS was -$0.32.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With ACTU analysts setting a high price target of 35.0 and a low target of 20.0, the average target price over the next 12 months is 29.0. Based on these targets, ACTU could surge 431.11% to reach the target high and rise by 203.49% to reach the target low. Reaching the average price target will result in a growth of 340.06% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$3.16 being high and -$3.16 being low. For ACTU, this leads to a yearly average estimate of -$3.16.
